TEGSEDI is a medicine that treats the polyneuropathy caused by hereditary transthyretin-mediated amyloidosis. TEGSEDI is for use in adults only.
Nerve damage from hereditary ATTR amyloidosis results from amyloid buildup which damages organs and tissues. Amyloid is made up of clusters of the TTR protein. TEGSEDI prevents the creation of TTR proteins, reducing the amount of amyloid that builds up.
- In a clinical trial, people who received TEGSEDI experienced significant reductions in TTR protein levels.
Timeline
No Timeline data yet.
Further Resources
No Further Resources data yet.
